Androgen deprivation therapy: Managing side effects

Australian Family Physician

Volumn 37, Issue 8, 2008, Pages 641-647

  Kabir, Shahrir ^a   Mancuse, Pascal ^b   Rashid, Preim ^c  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b PORT MACQUARIE BASE HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ARTICLE; HUMAN; MALE; PROSTATE TUMOR;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 53749083020     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. McLeod DG. Hormonal therapy: historical perspective to future directions. Urology 2003;61(2 Suppl 1):3-7.
2. Denis L, Murphy GP. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 1993;72(12 Suppl):3888-95.
3. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 2004;61:332-53.
4. Smith MR. Complementary and alternative therapies for advanced prostate cancer. Hematol Oncol Clin North Am 2001;15:559-71.
5. Holzbeierlein JM. Managing complications of androgen deprivation therapy for prostate cancer. Urol Clin North Am 2006;33:181-90.
6. Eaton AC, McGuire N. Cyproterone acetate in treatment of post-orchidectomy hot flushes. Double-blind cross-over trial. Lancet 1983;2:1336-7.
7. Quella SK, Loprinzi CL, Sloan J, et al. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol 19991;162:98-102.
8. Hammar M, Frisk J, Grimas O, Hook M, Spetz AC, Wyon Y. Acupuncture treatment of vasomotor symptoms in men with prostatic carcinoma: a pilot study. J Urol 1999;161:853-6.
9. Stearns V. Management of hot flashes in breast cancer survivors and men with prostate cancer. Curr Oncol Rep 2004;6:285-90.
10. Potosky AL, Knopf K, Clegg LX, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001;19:3750-7.
11. Fowler FJ, Jr., McNaughton Collins M, Walker Corkery E, Elliott DB, Barry MJ. The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer 2002;95:287-95.
12. Potosky AL, Reeve BB, Clegg LX, et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 2002;94:430-7.
13. Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 2003;61(2 Suppl 1):32-8.
14. Gomella L. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues. BJU Int 2007;99(Suppl):25-9.
15. Traish A, Kim N. The physiological role of androgens in penile erection: regulation of corpus cavemosum structure and function. J Sex Med 2005;2:759-70.
16. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154-64.
17. McLeod N, Huynh CC, Rashid P. Osteoporosis from androgen deprivation therapy in prostate cancer treatment. Aust Fam Physician 2006;35:243-5.
18. Mottet N, Prayer-Galetti T, Hammerer P, Kattan MW, Tunn U. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU Int 2006;98:20-7.
19. Seeman E, Melton LJ 3rd, O'Fallon WM, Higgs BL. Risk factors for spinal osteoporosis in men. Am J Med 1983;75:977-83.
20. Segal RJ, Reid RD, Coumeya KS, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2003;21:1653-9.
21. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008-12.
22. Saad F, McKieman J, Eastham J. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis. Urol Oncol 2006;24:4-12.
23. Zoledronic Acid. Pharmaceutical Benefits Schedule 2007.
24. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006;17:897-907.
25. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002;87:599-603.
26. Nishiyama T, Ishizaki F, Anraku T, Shimura H, Takahashi K. The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab 2005;90:657-60.
27. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-56.
28. Baade PD, Fritschi L, Eakin EG. Non-cancer mortality among people diagnosed with cancer (Australia). Cancer Causes Control 2006;17:287-97.
29. Chen AC, Petrylak DP. Complications of androgen-deprivation therapy in men with prostate cancer. Curr Urol Rep 2005;6:210-6.
30. McLeod DG, Iversen P. Gynecomastia in patients with prostate cancer. a review of treatment options. Urology 2000;56:713-20.
31. Karlsson CT, Malmer B, Wiklund F, Gronberg H. Breast cancer as a second primary in patients with prostate cancer-estrogen treatment or association with family history of cancer? J Urol 2006;176:538-43.
32. Bales G, Sinner M, Kim J, Chodak G. Impact of intermittent androgen deprivation on quality of life. J Urol 1996;155:1069.
33. Ross RW, Small EJ. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 2002;167:1952-6.
34. Hellerstedt BA PKJ. The truth is out there: an overall perspective on androgen deprivation. Urol Oncol 2003;21:272-81.
35. Wolff JM, Tunn UW. Intermittent androgen blockade in prostate cancer. rationale and clinical experience. Eur Urol 2000;38:365-71.
36. Tunn U. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight. BJU Int 2007;99 (Suppl 1):19-22; discussion 3-4.